As downregulation of the LRRC8A expression strongly reduced cell GBM cell numbers, our next important question was if targeting VRAC could enhance the effect of the chemotherapeutics, TMZ and carmustine, which are currently used in clinical settings. The gene discussed is LRRC8A; the disease is glioblastoma.